Fuad El-Hibri is the founder and executive chairman of the board of Emergent BioSolutions, Inc., of Rockville, Maryland. In this role, Fuad El-Hibri has maintained sales and profitability in the manufacture of vaccines for tuberculosis and influenza. Seeking to encourage further progress in basic and translational research, Mr. El-Hibri serves on the board of trustees of the International Biomedical Research Alliance.
The International Biomedical Research Alliance is a multidisciplinary group whose members include the National Institutes of Health, Cambridge University, and Oxford University. The alliance’s Scholars Program brings in students from the United States and Europe to conduct research with experts in the member institutions. The four-year endeavor enables students to pursue research agendas in the United States and the United Kingdom.
The scholars thrive in a results-oriented culture that promotes accessibility and permits them to work in open collaboration. They work with mentors who often come from biomedicine and other fields, such as mathematics and physics. This process frequently produces new discoveries, and every graduate of the program has single-authored one or more peer-reviewed articles.